Table 2.
List of OV delivering single Cytokine gene therapy discussed in this review
| OV NAME | THERAPEUTIC GENE | VIRUS TYPE | OV MUTATION | CANCER MODEL TESTED (EFFICACY) | REF. |
|---|---|---|---|---|---|
| Interleukin 12 Targeting OV: | |||||
| HSVM002 | IL-12α/IL-12β | HSV-1 | ΔICP34.5 | Neuroblastoma | [83] |
| NV1042 | IL-12α/IL-12β | HSV-1 | 15Kb deletion of UL56-ICP4 promotor region. | Squamous cell carcinoma (+). Hepatic (+). Prostate (+) |
[84, 88] [85] [87] |
| rVSV-IL12 | IL-12α/IL-12β | VSV | na | Squamous cell carcinoma | [90] |
| vMyxIL-12 | IL-12α/IL-12β | Myxoma | na | Not tested | [89] |
| Ad-DHscIL12 | IL-12α/IL-12β | Ad | Hypoxia controlled E1A (deleted for 24 b.p), and E2F-1 controlled E4. E1A gene, and Δ6.7K/gp19K E3 genes. | Pancreatic cancer | [92] |
| YKL-IL12 | IL-12α/IL-12β | Ad | E1B55kDa deleted | Melanoma (+) | [91] |
| Granulocyte Macrophage Targeting OV: | |||||
| NV1034 | GM-CSF | HSV-1 | 15Kb deletion of UL56-ICP4 promotor region. | Squamous cell Carcinoma (−) Prostate (−) Liver (+) Colorectal and Hepatoma. |
[84] [87] [96] [95] [95] |
| JS1/ICP34.5−/47− | GM-CSF | HSV-1 | ICP34.5−/−, and ICP47− | Lymphoma (+)* | [97] |
| E2F/GM/ΔE3 | GM-CSF | Ad | E2F regulated E1A and ΔE3 | Non small cell lung carcinoma (+) | E2F/G M/ΔE3 |
| CG0070 | GM-CSF | Ad | E2F re000gulated E1A. | Bladder transitional cell carcinoma (+) | [102] |
| TOA2 | GM-CSF | Ad | E2F and hTERT driven E1A, and ΔE3 | Lung cancer (+) | [104] |
| JX-594 | GM-CSF | VV | ΔTK | Liver cancer (+)** | [109] |
| MV GM-CSF | GM-CSF | MV | na | Lymphoid tumors (+) | [111] |
| Interleukin 24 Targeting OV: | |||||
| ZD55-IL-24 | IL-24 | Ad | E1B55kDa deleted | Colorectal carcinoma (+) Leukemia |
[112] [114] |
| Ad.PEG-E1A- mda-7 | IL-24 | Ad | PEG driven E1A | Prostate cancer (+) | [115] |
| AdCN103 | IL-24 | Ad | hTERT driven E1A, and Δ E3 | Hepatocellular carcinoma (+) | [116] |
| Ad.sp- E1A(Delta24)- IL-24 | IL-24 | Ad | Survivin driven E1A (with 24 bp deletion), and ΔE3 | Lung Cancer (+) | [117] |
| CRAdRGDflt- IL24 | IL-24 | Ad | Flt-1 driven E1A RGP peptide inserted knob domain. | Glioma(+) | [118] |
| B-Lymphocyte Activation Antigen B7-1: | |||||
| vHsv-B7.1-Ig | B7-1 | HSV-1 | ΔICP34.5−/−, ΔICP6 | Neuroblastoma (−) | [122] |
| G47ΔB7-1-Ig | Il-18 and B7-1 | HSV-1 | ΔICP34.5−/−, ΔICP6, and ICP47 | Prostate cancer (−) | [123] |
| Interleukin 4 Targeting OV: | |||||
| R8306 | IL-4 | HSV-1 | ΔICP34.5 | Glioma (+) | [127] |
| rHSVQ1-mIL4 | IL-4 | HSV-1 | ΔICP34.5, and ΔICP6 | Glioma (+) | [47] |
| HYPR-Ad-IL4 | IL-4 | Ad | Hypoxia regulated E1A, and ΔE3 | Glioma (+) | [128] |
| VSV-IL-4 | IL-4 | VSV | na | Breast and Melanoma | [129] |
| Interferon targeting OV: | |||||
| KD3-IFN | IFNα | Ad | Overexpression of ADP, and mutant E1A | Hepatocellular carcinoma | [135] |
| ZD-55- IFNβ | IFNβ | Ad | E1B55kDa deleted | Cervical Cancer model (+) | [137] |
| JX-795 | IFNβ | VV | ΔTK, ΔB18R | Murine tumor cell lines | [132] |
| CNHK300- mIFNγ | IFNγ | Ad | hTERT driven E1A | Liver Cancer models | [138] |
Abbreviations: IL-12: Interleukin 12; HSV-1: Herpes simplex virus 1; VSV: Vesicular Stomatitis virus; Ad: Adenovirus; MV: Measles virus; IL-24; Interleukin 24; B7-1: B-Lymphocyte Activation Antigen; IL-18: Interleukin 18; IL-4: Interleukin 4; IFN: Interferon; VV: Vacinia virus; MV: Measles virus;
*
Is currently being evaluated in human patients for efficacy [98].
**
Is currently being evaluated in human patients for efficacy [110]. IL-12: Interleukin 12; GM-CSF: Granulocyte macrophage stimulating factor.